Market Place
Sourcing Support
Khondrion Receives FDA Clearance for Sonlicromanol Phase 3
14 Nov 2024 //
GLOBENEWSWIRE
Khondrion`s Ph 2b Data on Sonlicromanol in Mitochondrial Disease
07 Nov 2024 //
GLOBENEWSWIRE
Khondrion appoints Jasper Levink as Chief Financial and Business Officer
11 Sep 2024 //
GLOBENEWSWIRE
Khondrion announces grant of patents in the US and Europe for sonlicromanol
01 Nov 2023 //
PR NEWSWIRE
Khondrion announces sonlicromanol Phase IIb progress
22 Nov 2022 //
GLOBENEWSWIRE
Khondrion forges on despite phase 2 mitochondrial disease fail
22 Nov 2022 //
FIERCEBIOTECH
Khondrion completes enrolment in Phase IIb trial evaluating sonlicromanol
10 Jan 2022 //
GLOBENEWSWIRE
Khondrion moves headquarters to Novio Tech Campus to support growth
26 Aug 2021 //
PRESS RELEASE
Khondrion announces first patients dosed in 6-month paediatric Phase II study
21 Apr 2021 //
GLOBENEWSWIRE
Khondrion, the clinical-stage pharmaceutical company discovering
06 Apr 2021 //
KHONDRION
Khondrion receives EMA agreement on its Paediatric Plan for sonlicromanol
18 Jan 2021 //
GLOBENEWSWIRE
Khondrion announces publication in Scientific Reports outlining
13 Jan 2021 //
PHARMIWEB
Khondrion shares progress of sonlicromanol development at Mitochondrial
30 Nov 2020 //
PHARMIWEB
Khondrion To Present At Mitocon’S 10Th Italian Meeting On Mitochondrial Diseases
07 Oct 2020 //
PRESSRELEASE
Khondrion highlights potential inflammatory lipid modulator prostaglandin E2
15 Apr 2020 //
PRESS RELEASE
Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol
27 Jan 2020 //
GLOBENEWSWIRE
Khondrion gears up for pivotal mitochondrial disease trial
27 Nov 2017 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.